For how we live.
In 120 older adults with acute myeloid leukaemia, adding midostaurin to two-drug therapy did not raise remission rates overall (72% vs 68%), but a small FLT3-mutated subgroup lived longer.
A proposed rule would cut the Part D generic copay from $1 to $0 for the lowest-income dual eligibles in 2028, tighten Medicare Advantage directory accuracy, and add PBM transparency rules. Comments close 15 December.
LOTIS-9 tested loncastuximab tesirine plus rituximab in unfit and frail older adults with untreated DLBCL. Complete responses reached 53% and 42%, but severe side effects, including 11 deaths, ended the trial early.
An Israeli records study of 181,000 adults found people now diagnosed are older and sicker, but start with better glucose and cholesterol, and far more leave the clinic on SGLT2 or GLP-1 drugs.
In the 17,701-person E.mbrace trial in adults 60 and older, the nine-valent ExPEC9V vaccine showed 14.63% efficacy, with a confidence interval spanning zero. It stopped early for futility; development is discontinued.
A prespecified analysis of 131,276 older adults found RSVpreF cut RSV hospitalisations overall. In the immunosuppressed, baseline risk was nine times higher — but the subgroup was too small to prove it helped them.
A phase 1/2 trial gave mosunetuzumab plus polatuzumab to 101 older, unfit or frail people with untreated large B-cell lymphoma. The end-of-treatment response rate was 61.4%, with a complete response in 56.4%.
In Scottish hospital data, RSV was recorded about 2.3 times as often as human metapneumovirus, but patients admitted with either virus were similarly ill — and the analysis was funded by a maker of RSV products.
A mandatory CMS payment model finalised 2 October recalculates inflation rebates for certain physician-administered drugs against an international benchmark, and can cut a patient's coinsurance to 10%.
A cluster-randomised trial in nearly 2,000 US nursing homes found fewer confirmed influenza outbreaks with a recombinant vaccine in a moderate flu season, but no difference in a near-flu-free one.
In the LOSE-AF trial, an eight-month low-calorie programme cut weight by 9.7% in older adults with AF. It did not change their symptoms, their AF burden, or their need for further rhythm treatment.
A US analysis of the 2025-2026 vaccines targeting the LP.8.1 lineage found both an mRNA-1283 and a BNT162b2 shot reduced COVID hospitalisation in older adults, with the strongest effect in those aged 75 and over.
In LatAm-FINGERS, 1,065 at-risk older adults across 11 countries did better on cognitive tests with structured coaching than with flexible health advice over two years. The gap was small.
The VITAL trial randomised 2,508 patients aged 50 and older to propofol-based or inhaled anaesthesia and found no difference in days alive and at home at 30 days, or in death, delirium or major complications.
REPLENISH randomised 381 patients with relapsed polymyalgia rheumatica. Sustained remission at 52 weeks reached about 41% on secukinumab versus 20.4% on placebo. Novartis funded the trial.
A warm bedroom measurably degrades sleep, and the best-studied comfortable band sits at roughly 20–25°C. The effect is real but personal, and heat matters more than most people assume.
A fine tremor everyone has — worsened by caffeine, stress, tiredness or some drugs — is the usual cause. Essential tremor is the commonest tremor disorder; a shake at rest is the one that points elsewhere.
A brief swim of light-headedness on standing is usually orthostatic hypotension: a fall in blood pressure as gravity pulls blood to the legs. It is common, rises with age, and often traces to dehydration or medication.
For most adults who bruise more than they used to, the cause is thinner skin from ageing, sun or steroids, plus the aspirin and anticoagulants many older people take. A few patterns point elsewhere.
Open-angle glaucoma steals side vision so slowly that half of people who have it don't know. There is no way to prevent it — but a placebo-controlled trial showed pressure-lowering drops preserve vision.
Losing the ability to walk is a turning point in later life. In a large randomised trial, structured activity cut the rate of major mobility disability — evidence that movement protects independence, read honestly.
Observational studies tie hearing loss to faster mental decline. But the first large randomised trial found no overall benefit from hearing aids over three years — with a signal of help only in higher-risk older adults.
Even frail people in their 80s and 90s roughly doubled their strength in ten weeks of training. But muscle size barely moved — the honest expectation is a big gain in function and a modest one on the scale.
If a choking person can still cough or speak, let them cough. If they cannot, the guideline sequence is five back blows then five abdominal thrusts, repeated — and new data suggests bystander action changes who survives.
Overactive bladder means urgency, often with frequency and night-time waking. Guidelines start with bladder training and fluid habits, and reserve drugs and procedures for when those fall short.
In 2,292 older adults, weak quadriceps tracked with higher mortality — but muscle size, measured by CT and DXA, did not. The finding reshaped how sarcopenia is defined and moved the target from bulk to strength.
A randomised trial and a 21-study meta-analysis found thyroid hormone normalised the blood test but left tiredness and symptom scores unchanged. A guideline now advises against routine treatment.
A Cochrane review of 36 trials found no strong evidence that any spray, gel or lozenge reliably relieves dry mouth. A second review found acupuncture no better than a placebo. The honest answers are narrow.
One cohort tied high animal protein in midlife to higher mortality, yet found the opposite after 65. Guidelines urge older adults to eat more, and plant protein looks best. No trial proves a lifespan effect.
Classic B12 deficiency is relatively uncommon, but it clusters: in people over 50 whose absorption fails, in vegans whose intake does, and around metformin, acid-lowering drugs and stomach surgery.
Everyday lapses are a poor guide to trouble. The line that matters is whether memory loss is measurable beyond your age and whether it is starting to affect daily function.
When brief vertigo is triggered by rolling over or looking up, it is usually a loose crystal in the inner ear. A Cochrane review found a repositioning manoeuvre resolved it in 56% versus 21%.
In a 619-patient NEJM trial of treatment-resistant depression after 60, augmenting an antidepressant with aripiprazole improved well-being more than switching to bupropion. The margin was modest.
Adults need about 2.4 micrograms a day, and most meat-eaters get it easily. Real deficiency clusters in older people, whose absorption fails, and in vegans, whose intake does.
Xerosis is a barrier problem, not dirt. Cochrane found moisturisers cut eczema flares 60% and spared steroid use; in care-home residents a twice-daily emollient roughly halved skin tears, on weak evidence.
A matched cohort of 173,910 people with dementia in England tied the drugs to raised risks of pneumonia, stroke, clots, heart attack, fracture and kidney injury — highest just after starting.
Swollen ankles are common with age. Chronic venous disease rises steeply over the years, and a very ordinary culprit is medication: calcium channel blockers caused ankle swelling in 10.7% of users versus 3.2% on placebo.
The official figure is 0.8 grams per kilogram of bodyweight a day — but that number is a floor to prevent deficiency, not a target for optimal health, and that distinction drives most of the argument.
Forgetting a name is not dementia, and a third of people diagnosed with mild cognitive impairment revert to normal. But that diagnosis still carries weight: risk of dementia stays elevated even in those who bounce back.
Losing a little height with age is expected. But marked loss tracks real risk: men who lost 3 cm or more had 45% higher mortality, and women who lost over 5 cm had roughly 50% higher hip-fracture risk.
TRIC-I-HF randomised 360 older patients with severe tricuspid regurgitation. Adding transcatheter repair to medical therapy cut a composite of death or heart-failure hospitalisation through three years.
One in five people get chronic itch at some point. When no rash and no cause turn up, a Cochrane review found almost no trials at all — leaving guideline experts to work from indirect evidence.
Balance starts slipping after the mid-50s. In 1,702 adults, those who could not hold a 10-second one-legged stance had 84% higher death risk. Specific exercise, done three times a week, measurably restores it.
Randomised trials show acute care delivered at home costs less, uses fewer tests and readmits fewer patients — while making little or no difference to whether they survive.
In 34,485 older adults, each 0.1 m/s of walking speed tracked with better survival. At age 75, predicted 10-year survival ran from 19% to 91% across the range — but speed reflects health, not the reverse.
Automatic fall alerts are mostly tested on staged laboratory falls, with real-world validation in older people rare. A 2026 meta-analysis of fall prediction found high specificity but only moderate sensitivity.
Planning ahead makes a patient's end-of-life wishes far more likely to be known and followed, and eases surviving families. What it has not reliably delivered is care that matches stated goals.
Cataract surgery was tied to 29% lower dementia risk in a strong cohort. But the largest hearing-aid trial found no overall effect on cognition. The signal is real; the proof that fixing senses prevents dementia is not.
Frailty has firm diagnostic criteria and predicts falls, hospital stays and death. It is also, unusually, treatable: resistance training raised muscle strength 113% even in nursing-home residents in their late 80s.
Structured counselling for a spouse delayed a patient's nursing-home admission by an estimated 557 days. Other trials cut carer depression sharply, though the effect on institutionalisation is less consistent.
EVAOLD tested whether stress imaging could safely spare patients aged 80 and over an invasive procedure. It was stopped early for futility, and the selective strategy did not prove non-inferior.
A landmark trial cut delirium from 15.0% to 9.9% by addressing six ordinary risk factors together. Drugs, including antipsychotics, have not shown the same clear preventive benefit.
Reviewing and stopping unnecessary drugs in older people is safe in trials and reduces inappropriate prescriptions. Whether it makes them live longer or feel better is far less settled than the enthusiasm implies.
Loneliness and isolation raise mortality risk about as much as well-known risk factors. But trials of interventions to relieve them in older people are mostly low-quality, and the best do more than arrange company.
Two pragmatic randomised trials and a Medicare nursing home cohort landed in the same week. Together they show real protection against hospitalisation and a durability question nobody has answered.
Pelvic-floor muscle training cured stress incontinence in 56% of women versus 6% on no treatment. Guidelines put it and bladder training first, ahead of medication.
A landmark cohort found strained spousal caregivers had a 63% higher death rate over four years. Decades of trials show interventions help — more for a carer's knowledge and mood than for the underlying burden.
In 2,292 hip fractures across six cities in Nagano, snowfall raised the odds of admission — until the models adjusted for how cold it was, at which point the association disappeared.
A Cochrane review finds fixing home hazards reduces falls by 38% in people at high risk of falling — and not at all in those who are not. On vitamin D, the US task force is blunt: no benefit.
Appetite fades with age and malnutrition is common and under-screened. Supplement drinks produce small, real weight gains — and cut deaths mainly in those already undernourished, not everyone.
A large trial in adults up to 89 found structured activity cut the risk of losing the ability to walk. In frail nursing-home residents near 90, strength training more than doubled muscle strength.
Sleep genuinely gets lighter and more broken with age, though only its efficiency keeps declining after 60. Insomnia itself is not normal ageing, and its first-line treatment is not a pill.
Coverage for adult vaccines like pneumococcal sits around a third of those eligible, far below targets. The evidence points less to refusal than to cost, insurance and the absence of a routine adult-vaccine visit.
Two vaccines cut RSV lower-respiratory illness in older adults by roughly two-thirds to four-fifths in their pivotal trials. US guidance now recommends them for everyone 75 and older and for high-risk adults from 50.
New conjugate vaccines replaced a confusing two-shot sequence with a single dose. The efficacy evidence is solid for the older conjugate; the newest ones ride on immune-response data, not their own outcome trials.
Reanalyzed EEG data from a phase 3 trial finds lemborexant and zolpidem leave distinct signatures on sleep architecture. Only the slow-oscillation increase predicted less insomnia severity.
In its pivotal trials the recombinant vaccine cut shingles cases by about 90 to 97 percent. Guidelines recommend two doses for adults from age 50, and for immunocompromised adults from 19.
A network meta-analysis of 41,084 surgical patients over 60 ranked 52 drug interventions. Dexmedetomidine held up after high-risk trials were excluded; almost nothing changed length of stay or mortality.
Standard questionnaires found no daytime difference between suvorexant and placebo. Four-times-daily smartphone prompts found fatigue worse in the morning and better later. The trial had 40 people.
In 311 adults aged 55 to 95, remission rates were 40% and 51% in the two intervention arms at one year, against 16% for online patient education. Adding human support helped a little.